Pharma giant Novartis (NOVN: VX) has scored a new European approval for Xolair (omalizumab), for people with severe chronic rhinosinusitis with nasal polyps.
The product can be marketed for adults as an add-on therapy, together with intranasal corticosteroids (INC), when INC alone has not worked.
Xolair is the first treatment for this condition which specifically targets and blocks immunoglobulin E (IgE), a key driver in the inflammatory pathway of the disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze